COX-2-dependent stabilization of survivin in non-small cell lung cancer 1 KOSTYANTYN KRYSAN † , FARRUKH H. MERCHANT || ,‡ ,‡ , LI ZHU ‡ , MARIAM DOHADWALA † , JIE LUO † , YING LIN † , NATHALIE HEUZE-VOURC’H † , MEHIS PÕLD † , DAVID SELIGSON § ,¶ , DAVID CHIA § ,†† ,¶ , LEE GOODGLICK § ,†† ,¶ , HEJING WANG §§ , ROBERT STRIETER * ,† , SHERVEN SHARMA ‡ and STEVEN DUBINETT * ,† ,‡ ,2 David Geffen School of Medicine at UCLA, * Division of Pulmonary and Critical Care; † UCLA Lung Cancer Research Program, Jonsson Comprehensive Cancer Center, Los Angeles; ‡ Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles; § Department of Pathology and Laboratory Medicine; || Department of Human Genetics; †† Jonsson Comprehensive Cancer Center; ¶ Early Detection Research Network and the UCLA Defined Tumor Marker Evaluation Center; §§ Department of Biomathematics, Los Angeles, California, USA 2 Correspondence: David Geffen School of Medicine at UCLA, Division of Pulmonary and Critical Care Medicine, 37-131 CHS, 10833 Le Conte Ave., Los Angeles, CA 90095-1690, USA. E-mail: sdubinett@mednet.ucla.edu <h3>SPECIFIC AIMS</h3> Cyclooxygenase 2 (COX-2) is frequently overexpressed in a variety of malignancies. The
/lp/fed-of-american-socs-for-experimental-biology/cox-2-dependent-stabilization-of-survivin-in-non-small-cell-lung-X6SIv00uNs